KR950000151A - 의약조성물 - Google Patents

의약조성물 Download PDF

Info

Publication number
KR950000151A
KR950000151A KR1019940013383A KR19940013383A KR950000151A KR 950000151 A KR950000151 A KR 950000151A KR 1019940013383 A KR1019940013383 A KR 1019940013383A KR 19940013383 A KR19940013383 A KR 19940013383A KR 950000151 A KR950000151 A KR 950000151A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
hydroxypropyl cellulose
weight
oral absorption
medicinal composition
Prior art date
Application number
KR1019940013383A
Other languages
English (en)
Inventor
도시히로 깃코지
다카유키 이시자와
지카코 하야다
마사토 오오타
Original Assignee
사사이 아키라
메이지세이카 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사사이 아키라, 메이지세이카 가부시키가이샤 filed Critical 사사이 아키라
Publication of KR950000151A publication Critical patent/KR950000151A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

(-)-(6R,7R)-7-[(Z)-2-(2-아미노티아졸-4-일)-2-메톡시이미노아세트아미드]-3-[(Z)-2-(4-메틸티아졸-5-일)에티닐]-8-옥소-5-티아-1-아자비시크로[4.2.0]옥토-2-엔-2-카르본산 2,2-디메틸프로피오닐옥시메틸에스텔(이하 세프디트렌피복실이라 칭함)의 쓴맛이 적은 경구 흡수개량 의약조성물을 제공한다. 세프디트렌피복실과 히드록시프로필셀루로즈를 함유시킴으로써, 경구흡수성이 우수한 쓴맛이 적은 적은 의약조성물이 얻어졌다. 세프디트렌피복실량에 대해 히드록시프로필셀루로즈를 0.4배 중량이상, 바람직하기로는 0.8~4배 중량 제제중에 배합한다.

Description

의약조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 본 발명 조성물 및 본 발명의 조성물의 용출곡선(n=3의 평균)을 표시, 제2도는 본 발명 조성물을 물에 현탁시켰을때의 현탁입자의 평균입경과 히드록시프로필셀루로즈/세프지트렌피복실의 배합비율의 관계를 표시, 제3도는 본 발명 조성물 및 본 발명의 조성물을 비글견(犬)에 경구 투여했을때의 혈장중 세프지트렌농도추이(n=8의 평균)을 표시.

Claims (2)

  1. 세프디트렌피복실과 히드록실프로필셀루로즈를 함유하는 것을 특징으로 하는 의약조성물.
  2. 제1항에 있어서, 세프디트렌피복실에 대한 히드록시프로필셀루로즈의 배합비가 0.4~4(중량비)인 의약조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019940013383A 1993-06-16 1994-06-14 의약조성물 KR950000151A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP93-144585 1993-06-16
JP5144585A JPH0717866A (ja) 1993-06-16 1993-06-16 医薬組成物

Publications (1)

Publication Number Publication Date
KR950000151A true KR950000151A (ko) 1995-01-03

Family

ID=15365534

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940013383A KR950000151A (ko) 1993-06-16 1994-06-14 의약조성물

Country Status (5)

Country Link
EP (1) EP0629404A1 (ko)
JP (1) JPH0717866A (ko)
KR (1) KR950000151A (ko)
CN (1) CN1105240A (ko)
CA (1) CA2125936A1 (ko)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
AR004014A1 (es) * 1995-10-13 1998-09-30 Meiji Seika Kaisha Una composicion antibacteriana de cefditoren pivoxilo para administracion oral y metodo para obtener dicha composicion
PL194097B1 (pl) * 1998-01-07 2007-04-30 Meiji Seika Kaisha Kompozycja zawierająca krystalograficznie trwałą amorficzną cefalosporynę i sposób jej wytwarzania
JP4827367B2 (ja) * 2000-11-21 2011-11-30 杏林製薬株式会社 ドライシロップ剤
CA2449002C (en) * 2001-05-29 2011-08-16 Tap Pharmaceutical Products Inc. Enhancement of oral bioavailability of non-emulsified formulation of prodrug esters with lecithin
WO2003097102A1 (fr) * 2002-05-22 2003-11-27 Shionogi & Co., Ltd. Preparation pharmaceutique dans laquelle la propriete de dissolution d'un medicament faiblement soluble dans l'eau est amelioree
WO2004030673A1 (ja) 2002-10-02 2004-04-15 Meiji Seika Kaisha, Ltd. 経口吸収性が改善された抗菌性医薬組成物
JP4640821B2 (ja) * 2003-07-24 2011-03-02 塩野義製薬株式会社 難水溶性薬物を含むドライシロップ剤
ATE539738T1 (de) * 2003-10-08 2012-01-15 Meiji Seika Pharma Co Ltd Nichtkristalline antibakterielle zusammensetzung mit cefditoren-pivoxil
JP2005162696A (ja) * 2003-12-04 2005-06-23 Nichiko Pharmaceutical Co Ltd 溶出性に優れたセフジトレンピボキシル製剤
KR20070040389A (ko) * 2004-08-10 2007-04-16 아지노모토 가부시키가이샤 쓴 맛이 감소된 나테글리니드 함유 제제
WO2008057058A1 (en) * 2006-11-10 2008-05-15 Nobel Ilac Sanayii Ve Ticaret As Oral pharmaceutical compositions
WO2012010938A2 (en) * 2010-07-23 2012-01-26 Lupin Limited Pharmaceutical compositions of cefditoren pivoxil
CN102846570B (zh) * 2012-09-13 2013-10-23 山东罗欣药业股份有限公司 一种头孢妥仑匹酯组合物片剂及其制备方法
KR101561963B1 (ko) * 2013-05-23 2015-10-22 영진약품공업 주식회사 세프디토렌 피복실의 신규 결정 형태 및 이의 제조 방법
EP3244879A1 (en) 2015-01-16 2017-11-22 Ögün, Yusuf Toktamis Cefditoren pivoxil compositions with improved stability and production methods thereof
CN110251467A (zh) * 2019-06-26 2019-09-20 北京济美堂医药研究有限公司 一种无定形态头孢妥仑匹酯组合物的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0678234B2 (ja) * 1988-04-19 1994-10-05 明治製菓株式会社 経口投与用抗菌組成物

Also Published As

Publication number Publication date
EP0629404A1 (en) 1994-12-21
CA2125936A1 (en) 1994-12-17
JPH0717866A (ja) 1995-01-20
CN1105240A (zh) 1995-07-19

Similar Documents

Publication Publication Date Title
KR950000151A (ko) 의약조성물
US4665081A (en) Solid nifedipine preparations and a process for preparing same
JP2916152B2 (ja) 薬物放出速度調節型製剤
IE881452L (en) Pharmaceutical composition
Klepser et al. Clinical pharmacokinetics of newer cephalosporins
WO2004060351A3 (en) Pharmaceutical formulation with an insoluble active agent for pulmonary administration
US4620974A (en) Pharmaceutical composition containing a liquid lubricant
JPH0399012A (ja) 経口投与可能なｎ―アセチル―システイン含有製剤
WO2008057058A1 (en) Oral pharmaceutical compositions
CA1334934C (en) Antibacterial composition for oral administration
CN104644610A (zh) 一种头孢氨苄胶囊
CA2388325A1 (en) Ciclesonide-containing aqueous pharmaceutical composition
TW201004625A (en) A fine grain agent having improved water-suspensibility
CZ138595A3 (en) Easily re-dispersible and chemically stable pharmaceutical preparation containing cefixim
Bryskier et al. The pharmacokinetics of cefodizime following intravenous and intramuscular administration of a single dose of 1.0 g
EP0867181A1 (en) Nasal melatonin composition
KR870010082A (ko) 구아르(guar) 분말
Rattie et al. Acetaminophen prodrugs III: Hydrolysis of carbonate and carboxylic acid esters in aqueous buffers
JP4841130B2 (ja) 安定化されたビタミン製剤
GB1479655A (en) Antibiotic preparations
US5525596A (en) Absorption enhancer/solubilizer combination for improved bioavailability of a zwitterionic compound
US4777048A (en) Pharmaceutical composition containing a liquid lubricant
JP2006219462A (ja) 経口製剤用粒子
US4406888A (en) Aqueous micellar solutions of levonantradol and N-methyllevonantradol and lyophilic forms thereof for reconstitution
NZ212763A (en) Ph-3- (1-pyridiniummethyl)-3-cephem-4- carboxylate pentahydrate and amorphous lactose

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid